Brenntag Expands Biopharma Capabilities in EMEA with Acquisition of mcePharma

Brenntag Expands Biopharma Capabilities in EMEA with Acquisition of mcePharma

(IN BRIEF) Brenntag has acquired mcePharma a.s. in the Czech Republic to expand its capabilities in the pharmaceutical and biopharmaceutical value chain across EMEA. This acquisition strengthens Brenntag’s GMP services, including biobuffers and liquid blending, to meet growing demand in the biopharma sector. With advanced GMP facilities and expertise in OTC product development and packaging, the acquisition allows Brenntag to provide high-quality, customer-focused solutions to the rapidly growing biopharma market in EMEA and globally.

(PRESS RELEASE) ESSEN, 5-Jun-2025 — /EuropaWire/ — Brenntag, the global leader in chemicals and ingredients distribution, has announced the acquisition of mcePharma a.s., based in the Czech Republic. This strategic acquisition, coupled with additional investments at the mcePharma site, will strengthen Brenntag’s position across the pharmaceutical and biopharmaceutical value chain in the EMEA region, setting the foundation for a central hub of GMP (Good Manufacturing Practice) value-added services.

The acquisition enhances Brenntag’s capabilities in GMP blending and down-packing, with a specific focus on integrating GMP biobuffers and liquid blending. This expansion is designed to meet the increasing demand from customers and supply partners in the rapidly growing biopharma market. The existing state-of-the-art GMP facilities, along with advanced sampling services and expertise in OTC product development and GMP powder pack-off, will significantly bolster Brenntag Pharma’s offering to both customers and principals.

Joakim Rehné, President of Pharma EMEA at Brenntag, commented, “By integrating GMP blending and down-packing, and expanding warehouse and office space, we are positioning ourselves to meet the growing demand for high-quality biopharmaceutical solutions. This acquisition is a powerful addition to our portfolio, reinforcing our commitment to operational excellence, speed, and customer-centric solutions.”

Ivan Mikes, Member of the Administration Board of mcePharma, expressed excitement about the partnership: “We are thrilled to expand our reach and customer base by joining Brenntag. Our team will now have the opportunity to leverage Brenntag’s expertise, allowing us to serve customers across the entire EMEA region, alongside Brenntag Pharma colleagues.”

Gust Desmedt, Global President of Pharma at Brenntag Specialties, added, “This acquisition is a significant milestone in our strategic efforts to enhance our biopharmaceutical services, complementing our offerings in traditional small molecules. With the additional capabilities mcePharma brings, we are confident in our ability to serve more customers and supply partners with specialized biobuffers in the rapidly expanding biopharma market in EMEA and globally.”

The financial details of the acquisition have not been disclosed, with both the signing and closing of the transaction occurring simultaneously.

Media Contacts:

Verena Blaschke
Brenntag SE
Senior Vice President Global Communications
+49 201 6496 1213
verena.blaschke@brenntag.com

Robert Reitze
Brenntag SE
Press Officer Global Communications
+49 201 6496 2128
Robert.Reitze@brenntag.com

SOURCE: Brenntag SE